Acacia Pharma reports positive results from APD515 Stage II research for treatment of xerostomia Acacia Pharma, a pharmaceutical company specialising in the development of medicines for supportive treatment, announces positive results from its Phase II research of APD515 for the treating xerostomia in advanced cancer individuals. The analysis showed that APD515 significantly reduced the symptoms of dry mouth in comparison to placebo. APD515 is an optimised oromucosal formulation of a presently marketed muscarinic agonist for the completely new, patent-protected usage of treatment of xerostomia. Dr Julian Gilbert, Acacia Pharma's CEO commented, ‘We are delighted with these results.‘In comparison to their healthy peers, children with congenital cardiovascular disease have impaired development, as measured in excess weight, length, and mind circumference,’ said senior author Meryl S. Cohen, M.D., a pediatric cardiologist in the Cardiac Middle at The Children's Medical center of Philadelphia. ‘We investigated patterns of poor development in these children, as a starting place in guiding us toward far better treatments.’ Related StoriesAggressive blood pressure treatment can decrease risks of heart disease and deathAngina in women associated with abnormal heart bloodstream flowNew 3D imaging technology lets experts look at earliest indications of heart disease In the January 2013 issue of Pediatrics The study appeared while an online article.